In hospitals across the U.S., a familiar ritual unfolds for every newborn: a nurse pricks the baby’s heel and stamps blood onto a special filter paper. This simple test—standard for over 50 years—screens for treatable conditions like sickle cell anaemia and cystic fibrosis. But today, a new frontier is emerging: using that same blood spot to uncover a baby’s genetic risk for diseases that may develop decades later, including autism or adult cancers.
Genome Sequencing Gains Ground
As genome sequencing becomes faster and more affordable, thousands of parents are enrolling their healthy newborns in research studies. These programmes analyse hundreds of genes to uncover potential health risks. While some parents view this as a proactive step, others question the value of knowing a child’s predisposition to untreatable conditions. Should we unlock such data when there’s no cure or intervention?
Ethical dilemmas abound. Some experts argue that predicting adult-onset conditions violates the child’s future right to remain unaware. Others believe such insights could guide early therapies, especially for neurological conditions like autism.
Acting on the Data: Hope or Harm?
Dr Wendy Chung’s pioneering study in New York offers sequencing results for over 450 conditions. More than 90% of participating parents have chosen to receive information—even about incurable diseases. The goal is early intervention. For instance, knowing a child’s autism risk may enable speech and occupational therapy during critical brain development years, potentially improving life outcomes.
“Parents told us they’d rather feel empowered than stay in the dark,” Dr Chung said.
India’s Slow but Steady Progress
As reported by TOI, India lacks a national newborn screening programme, though states like Kerala offer limited free testing. Both public and private hospitals routinely conduct paid screenings for conditions like congenital heart defects and metabolic disorders. Increasingly, private labs now offer advanced genetic panels using Next-Generation Sequencing (NGS), costing between ₹5,000 and ₹25,000.
However, such testing remains selective. Dr Jayashree Mondkar, senior neonatologist and former dean at Sion Hospital, Mumbai, cautions that full genetic screening isn’t necessary for all newborns. “For rare but serious disorders like SMA or Gaucher’s disease, early diagnosis can guide treatment and reduce long-term burdens,” she explains. “But we usually recommend it only in high-risk cases.”
Looking Ahead
As genome technology becomes more accessible, the challenge lies in drawing ethical boundaries. While the potential to maximise a child’s future health is promising, it raises profound questions about knowledge, choice, and responsibility.